Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Crohn's Disease: full-pipeline trial registry
37 of 106 indexed Crohn's Disease trials are currently recruiting.
Corpus placement: #122 of 28,707 conditions by registered trial count.
106 US clinical trials · 37 currently recruiting · #122 of 28,707 conditions by registered trial count
Crohn's Disease: 106 US clinical trials tracked, 37 recruiting.
Crohn's Disease is the subject of 106 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 46 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Takeda, running 13 of these trials.
Enrollment posture brief
Registry condition crohns-disease
OPEN 37 | RECR 35% | LATE 46 | EARLY 36 | RANK #122 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Hemophilia A (35% recruiting · 43 trials)
Crohn's Disease lists 37 open slots (35% of 106 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Crohn's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Crohn's Disease is recruiting below its size-band peers.
37 of 106 indexed trials (34.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Crohn's Disease trials is spread across many organizations.
Takeda accounts for 13 of 106 trials (12.3%). 52 distinct sponsors appear on at least one study for this condition label.
-
Typical Crohn's Disease enrolment sits around 196 participants.
Median target enrolment is 196 among the 106 trials that report a genuine target (sentinel values excluded). 36 of those (34%) plan for fewer than 100 participants.
-
Crohn's Disease research is mostly interventional.
90 interventional and 16 observational studies make up this index (84.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
106 total, page 1 of 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Merck Sharp & Dohme
NCT06430801
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Sanofi
NCT07184931
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Sanofi
NCT07184944
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
Weill Medical College of Cornell University
NCT03256240
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie
NCT06548542
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Takeda
NCT06581328
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Takeda
NCT06227910
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
NCT06226883
Helmsley 3.0: Abbreviated MRE
Children's Hospital Medical Center, Cincinnati
NCT06533228
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
Alimentiv
NCT06249555
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
TScan Therapeutics
NCT06587828
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
NCT06937099
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Takeda
NCT06233461
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Sanofi
NCT06637631
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda
NCT05442567
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development
NCT06663332
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Takeda
NCT06764615
Behavioral Therapy for Crohn's Disease
Icahn School of Medicine at Mount Sinai
NCT06512597
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Eli Lilly and Company
NCT04844606
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Mirador Therapeutics
NCT07113522
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Weill Medical College of Cornell University
NCT06274554
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development
NCT05923073
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Janssen-Cilag
NCT06408935
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
AbbVie
NCT05995353
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
AbbVie
NCT06332534
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Takeda
NCT06045754
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
Sanofi
NCT06958536
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
NCT05509777
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Takeda
NCT06100289
Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
Alimentiv
NCT06670638
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
Icahn School of Medicine at Mount Sinai
NCT06001450
68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease
Mayo Clinic
NCT07273188
Treatment of Moderate to Severe Refractory Crohn's Disease
Tr1X
NCT06721962
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03167437
Autologous Stem Cell Transplantation for Crohn's Disease
Paul Szabolcs
NCT00692939
Beta-Hydroxybutyrate Feasibility Treating IBD
University of Texas at Austin
NCT06351124
A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
Mayo Clinic
NCT06647615
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Target PharmaSolutions
NCT03251118
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Janssen Biotech
NCT00606346
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
AbbVie
NCT02130362
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development
NCT03466411
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
AbbVie
NCT03105102
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company
NCT04232553
OTIS Cimzia Pregnancy Registry
University of California, San Diego
NCT01797224
A Study of Surgical Interventions in Fistulizing Conditions
Takeda
NCT04940611
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie
NCT03345823
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development
NCT05242471
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie
NCT06063967
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
Takeda
NCT04809363
Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
Avobis Bio
NCT04847739
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 22 |
| Phase 3 | 41 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Crohn's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Crohn's Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Crohn's Disease page
106 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Crohn's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Takeda sponsors the most Crohn's Disease trials on record, review their full trial history before evaluating a specific study. See Takeda's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Crohn's Disease condition card totals 106 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.